Final phase trials in Brazil for the Chinese vaccine Sinovac Biotech COVID-19 have shown promising results, positioning it for public use, The Wall Street Journal reported Monday.
According to the newspaper, the vaccine, CoronaVac, has reached phase three of trials in Brazil, the first country to complete the third stage of testing the Sinovac vaccine. The experimental vaccine is also being tested in Indonesia and Turkey.
Sources involved in the development of the vaccine told the newspaper that the results of the trial in Brazil indicate that the Sinovac vaccine is above 50% of the threshold that the scientific community has considered necessary for sufficient protection against the virus. .
João Doria, governor of São Paulo, has said the plan is to vaccinate all of São Paulo by the end of July, a year faster than the Brazilian federal government has promised. São Paulo represents approximately one-fifth of the country’s population.
In October, Sinovac reported that 10,000 residents had already been injected into Beijing with their vaccine.
News of promising results from Sinovac follow similar reports about another possible vaccine, from Chinese state-owned pharmaceutical company Sinopharm.
The UAE reported earlier this month that its trial with the Sinopharm vaccine candidate indicated that it was 86% effective in preventing coronavirus and 100% effective in preventing moderate to severe cases of COVID. -19. The United Arab Emirates approved the Sinopharm vaccine on December 10, becoming the first government to do so.